A citation-based method for searching scientific literature

Harold E Bays, Christie M Ballantyne, Rene A Braeckman, William G Stirtan, Paresh N Soni. Am J Cardiovasc Drugs 2013
Times Cited: 89







List of co-cited articles
726 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
68

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
217
66


Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
43

Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
32



Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Terry A Jacobson, Sara B Glickstein, Jonathan D Rowe, Paresh N Soni. J Clin Lipidol 2012
169
25

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2016
32
71

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Michael Miller, Neil J Stone, Christie Ballantyne, Vera Bittner, Michael H Criqui, Henry N Ginsberg, Anne Carol Goldberg, William James Howard, Marc S Jacobson, Penny M Kris-Etherton,[...]. Circulation 2011
24

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
24

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
572
24

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
Yasushi Saito, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Atherosclerosis 2008
204
24

Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
Ryo Nishio, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Takumi Inoue, Amane Kozuki, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi,[...]. Atherosclerosis 2014
66
31

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Rene A Braeckman, Mehar S Manku, Harold E Bays, William G Stirtan, Paresh N Soni. Prostaglandins Leukot Essent Fatty Acids 2013
36
58

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Jean-Claude Tardif, Steven B Ketchum, Ralph T Doyle, Sabina A Murphy, Paresh N Soni,[...]. Clin Cardiol 2017
102
23

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
277
22

Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
947
21

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Bernhard Rauch, Rudolf Schiele, Steffen Schneider, Frank Diller, Norbert Victor, Helmut Gohlke, Martin Gottwik, Gerhard Steinbeck, Ulrike Del Castillo, Rudolf Sack,[...]. Circulation 2010
378
20

n-3 fatty acids and cardiovascular events after myocardial infarction.
Daan Kromhout, Erik J Giltay, Johanna M Geleijnse. N Engl J Med 2010
611
20

n-3 fatty acids in patients with multiple cardiovascular risk factors.
Maria Carla Roncaglioni, Massimo Tombesi, Fausto Avanzini, Simona Barlera, Vittorio Caimi, Paolo Longoni, Irene Marzona, Valentina Milani, Maria Giuseppina Silletta, Gianni Tognoni,[...]. N Engl J Med 2013
320
20


Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
R Preston Mason, Robert F Jacob, Sandeep Shrivastava, Samuel C R Sherratt, Amitabha Chattopadhyay. Biochim Biophys Acta 2016
68
26

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Abbie L Cawood, Ren Ding, Frances L Napper, Ruth H Young, Jennifer A Williams, Matthew J A Ward, Ola Gudmundsen, Runar Vige, Simon P K Payne, Shu Ye,[...]. Atherosclerosis 2010
142
19

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
John J P Kastelein, Kevin C Maki, Andrey Susekov, Marat Ezhov, Borge G Nordestgaard, Ben N Machielse, Douglas Kling, Michael H Davidson. J Clin Lipidol 2014
148
19


Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
124
19

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
358
19

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
Harold E Bays, Rene A Braeckman, Christie M Ballantyne, John J Kastelein, James D Otvos, William G Stirtan, Paresh N Soni. J Clin Lipidol 2012
51
31

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
Christie M Ballantyne, Rene A Braeckman, Harold E Bays, John J Kastelein, James D Otvos, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2015
27
59

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rene A Braeckman, William G Stirtan, Paresh N Soni, Rebecca A Juliano. Atherosclerosis 2016
26
61

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
335
17


Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
870
16


Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia.
Nobuaki Tanaka, Tatsuro Ishida, Manabu Nagao, Takeshige Mori, Tomoko Monguchi, Maki Sasaki, Kenta Mori, Kensuke Kondo, Hideto Nakajima, Tomoyuki Honjo,[...]. Atherosclerosis 2014
49
30

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
Om P Ganda, Deepak L Bhatt, R Preston Mason, Michael Miller, William E Boden. J Am Coll Cardiol 2018
94
16

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
127
16

Relationships between plasma fatty acid composition and coronary artery disease.
Hiroshige Itakura, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita,[...]. J Atheroscler Thromb 2011
155
15


Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
15

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
15


A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro,[...]. J Cardiol 2017
65
21


Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome.
Noriko Satoh, Akira Shimatsu, Kazuhiko Kotani, Naoki Sakane, Kazunori Yamada, Takayoshi Suganami, Hideshi Kuzuya, Yoshihiro Ogawa. Diabetes Care 2007
97
14

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Kevin C Maki, David G Orloff, Stephen J Nicholls, Richard L Dunbar, Eli M Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H Davidson. Clin Ther 2013
76
15

Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia.
Noriko Satoh-Asahara, Akira Shimatsu, Yousuke Sasaki, Hidenori Nakaoka, Akihiro Himeno, Mayu Tochiya, Shigeo Kono, Tomohide Takaya, Koh Ono, Hiromichi Wada,[...]. Diabetes Care 2012
46
26

Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound.
Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshio Taketani, Hiroyasu Oeduka, Kenya Kusunose, Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki,[...]. Circ J 2016
48
25

Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
J R Nelson, O Wani, H T May, M Budoff. Vascul Pharmacol 2017
42
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.